Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01868464 · ClinicalTrials.gov registry record · Phase 1
Challenge Model for Assessment of Human TB Immunity
A Phase 1 study of Tuberculosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
- 2
- Study locations
NCT01868464: Completed Phase 1 study of Tuberculosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT01868464 is a Phase 1 study of Tuberculosis that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 92 participants, below the 931-participant average among 29 other Tuberculosis trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01868464, a Phase 1 study of Tuberculosis, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase I open-label, dose escalation trial to evaluate the use of Tice® BCG as a challenge for future assessment of in vivo TB immunity. Subjects will be recruited from the target population reflecting the community at 2 VTEU sites. Enrollment will occur over 14 months. Subjects who provide informed consent will be screened, and up to 120 eligible, HIV and TB uninfected subjects, 18-45 years, inclusive, will be enrolled for study interventions and sequentially assigned to 1 of 4 dose groups. Doses of Tice BCG from 2 to 16x10\^6 cfu will be delivered ID in a dose escalation format to 4 groups of 30 subjects per dose group. Primary Objectives: 1) Evaluate the safety of different doses of ID Tice BCG for use as a human challenge model for TB infection. 2) Examine shedding from ID challenge sites after administration of different doses of Tice BCG in TB naive healthy subjects. 3) Evaluate the reproducibility of BCG shedding over time with both quantitative PCR and culture.
Conditions Studied
Interventions
- BIOLOGICAL BCG TICE strain
Study Locations (2)
Georgia
- Emory Vaccine Center - The Hope Clinic - Decatur
Missouri
- Saint Louis University - Center for Vaccine Development - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2014-05-28 |
| Est. Completion | 2017-12-18 |
| Phase | Phase 1 |
What the finished NCT01868464 record still lists
NCT01868464 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 931-participant average among 29 other Tuberculosis trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Tuberculosis appearing as the primary indexed condition, and to 1 intervention - of which BCG TICE strain is the first listed.
NCT01868464 reports a single indexed study location in Georgia, Missouri.
Frequently Asked Questions
What is clinical trial NCT01868464 about?
NCT01868464 is a clinical study titled "Challenge Model for Assessment of Human TB Immunity". This is a Phase I open-label, dose escalation trial to evaluate the use of Tice® BCG as a challenge for future assessment of in vivo TB immunity. Subjects will be recruited from the target population reflecting the community at 2 VTEU sites. Enrollment will occur over 14 months. Subjects who provide...
What is the current status of trial NCT01868464?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2014-05-28. Estimated completion is 2017-12-18.
What conditions does trial NCT01868464 study?
This clinical trial studies the following conditions: Tuberculosis.
What interventions are being tested in trial NCT01868464?
The interventions under investigation include: BCG TICE strain (BIOLOGICAL).
Who is sponsoring clinical trial NCT01868464?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01868464 being conducted?
This trial has 2 study locations across Georgia, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tuberculosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01868464's enrollment target sits among peer trials
92 19th of 29 higher than 11 of 29 other Tuberculosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tuberculosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
COMPLETED · Phase 1
-
Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers
COMPLETED · Phase 1
-
Phase I Trial of DAR-901
COMPLETED · Phase 1
-
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis
COMPLETED · Phase 1
-
A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
COMPLETED · Phase 1
-
Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI